Cargando…
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
BACKGROUND: The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known. METHODS: In this ongoing, phase 2–3 study, we compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger R...
Autores principales: | Chalkias, Spyros, Harper, Charles, Vrbicky, Keith, Walsh, Stephen R., Essink, Brandon, Brosz, Adam, McGhee, Nichole, Tomassini, Joanne E., Chen, Xing, Chang, Ying, Sutherland, Andrea, Montefiori, David C., Girard, Bethany, Edwards, Darin K., Feng, Jing, Zhou, Honghong, Baden, Lindsey R., Miller, Jacqueline M., Das, Rituparna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511634/ https://www.ncbi.nlm.nih.gov/pubmed/36112399 http://dx.doi.org/10.1056/NEJMoa2208343 |
Ejemplares similares
-
LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2022) -
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2023) -
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
por: Chalkias, Spyros, et al.
Publicado: (2023) -
Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022) -
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
por: Chalkias, Spyros, et al.
Publicado: (2022)